Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS).

ABSTRACT:

Objective

To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings.

Methods

This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib) from 1 January 2015 to 30 June 2021. The primary outcome was a serious infection (ie, requiring hospitalisation), in a time-to-event analysis using propensity score-weighted Cox models, with adalimumab as the comparator, estimating weighted HRs (wHRs) and their 95% CIs.

Resul

SUBMITTER: Bastard L 

PROVIDER: S-EPMC10941117 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature